BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38233537)

  • 1. Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia.
    Yasuta Y; Kaminaka R; Nagai S; Mouri S; Ishida K; Tanaka A; Zhou Y; Sakurai H; Yokoyama S
    Sci Rep; 2024 Jan; 14(1):1525. PubMed ID: 38233537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
    Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
    Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
    Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
    Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic BRAF
    Shabaneh TB; Molodtsov AK; Steinberg SM; Zhang P; Torres GM; Mohamed GA; Boni A; Curiel TJ; Angeles CV; Turk MJ
    Cancer Res; 2018 Sep; 78(17):5038-5049. PubMed ID: 30026331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
    Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
    Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
    Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
    Nogueira C; Kim KH; Sung H; Paraiso KH; Dannenberg JH; Bosenberg M; Chin L; Kim M
    Oncogene; 2010 Nov; 29(47):6222-32. PubMed ID: 20711233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RAC1 Target NCKAP1 Plays a Crucial Role in the Progression of Braf;Pten-Driven Melanoma in Mice.
    Swaminathan K; Campbell A; Papalazarou V; Jaber-Hijazi F; Nixon C; McGhee E; Strathdee D; Sansom OJ; Machesky LM
    J Invest Dermatol; 2021 Mar; 141(3):628-637.e15. PubMed ID: 32777214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MC1R is a potent regulator of PTEN after UV exposure in melanocytes.
    Cao J; Wan L; Hacker E; Dai X; Lenna S; Jimenez-Cervantes C; Wang Y; Leslie NR; Xu GX; Widlund HR; Ryu B; Alani RM; Dutton-Regester K; Goding CR; Hayward NK; Wei W; Cui R
    Mol Cell; 2013 Aug; 51(4):409-22. PubMed ID: 23973372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
    Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
    Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
    Kim JE; Stones C; Joseph WR; Leung E; Finlay GJ; Shelling AN; Phillips WA; Shepherd PR; Baguley BC
    BMC Cancer; 2012 Apr; 12():141. PubMed ID: 22475322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.